For Healthcare Professionals

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

clipboard-pencil

About the study

The purpose of this study is to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR). This evaluation will provide information that brolucizumab is non-inferior to PRP with respect to the change in best corrected visual acuity at Week 54.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Signed informed consent must be obtained prior to participation
  2. Able to complete adequate fundus photographs and retinal images
  3. Diagnosis of type 1 or 2 Diabetes Mellitus (DM) and HbA1c less than or equal to 12% at screening
  4. DM treatment stable for at least 3 months
  5. PDR diagnosis with no previous PRP treatment in the study eye

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Concomitant conditions or ocular disorders in the study eye at Screening or Baseline that could compromise a response to study treatment.
  2. Presence of diabetic macular edema in the study eye
  3. Active infection or inflammation in the study eye
  4. Uncontrolled glaucoma (IOP greater than 25 mmHg)
  5. Intravitreal anti-VEGF treatment within 6 months
  6. Treatment with intraocular corticosteroids
  7. End stage renal disease requiring dialysis or kidney transplant
  8. Uncontrolled blood pressure
  9. Systemic anti-VEGF therapy at any time

Other protocol-defined inclusion/exclusion criteria may apply.


pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Proliferative Diabetic Retinopathy

Age (in years)

18+

Phase

Phase 3

Participants needed

694

Est. Completion Date

Aug 20, 2024

Treatment type

Interventional


Sponsor

Novartis

ClinicalTrials.gov identifier

NCT04278417

Study number

CRTH258D2301

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.